According to Bloomberg, the eighteen rating agencies currently monitoring Amgen Inc. (NASDAQ: AMGN) have collectively assigned the company a “Hold” rating for the stock, making it the consensus recommendation. There are a total of ten research analysts here, and four of them think that the stock should be sold, five think that it should be kept, and the remaining ten think it should be bought. Recent research from brokerage firms indicates that the stock should reach a price of $248.19 during the next year.
The stock has received the opinions of several research analysts. Oppenheimer increased their price objective for Amgen shares to $300.00 in a report that was published on November 15, and the report was distributed on Tuesday. Atlantic Securities lowered their target price on Amgen shares from $190.00 to $182.00 and gave the company an “underweight” rating in a research report published on Tuesday, August 9. Morgan Stanley increased their price target on Amgen from $279.00 to $282.00 and gave the stock an “overweight” rating in a research report published on Friday, November 4. Trust Financial increased its target price on Amgen shares from $266.00 to $280.00 and set the stock to a “hold” rating in a research report released on Tuesday, November 8. Finally, on October 12, a research note was published on StockNews.com’s website announcing the website’s intention to cover shares of Amgen. They suggested that the organization make a “purchase” decision.
In a transaction that took place on November 8, Senior Vice President Nancy A. Grygiel sold 545 shares of Amgen stock. At an average price of $293.54 per share, the stock was sold for a total of $159,979.30, which brings the total n s $159,979.30. Because of the transaction, the senior vice president now directly owns 13,009 shares of the company’s stock, which have a combined value of $3,818,661.86. This information about the transaction was published in a filing with the Securities and Exchange Commission, which can be located here. There is insider ownership of 0.46% of the total business stock.
Recently, hedge funds and other institutional investors have increased or decreased their stock holdings. During the third quarter, EdgeRock Capital LLC acquired a new investment in Amgen by making a payment of roughly $25,000. The amount of ownership in Amgen held by Leelyn Smith LLC rose by 80.3% during the third quarter. As a result of the most recent purchase of 49 additional shares, Leelyn Smith LLC now has a total of 110 shares of the stock of the medical research firm, which has a value of $25,000. During the first three months of 2018, Rational Advisors LLC purchased a new interest in Amgen valued at around $26,000. During the second quarter, Capital Wealth Alliance LLC acquired a new interest in Amgen valued at close to $26,000. Last but not least, during the second quarter, Coston McIsaac & Partners shelled out nearly $27,000 to acquire a new position at Amgen. The company’s stock is owned by hedge funds and other types of institutional investors to the extent of 77.14%.
AMGN stock started the trading day on Wednesday at $287.05 per share. The company has a simple moving average of $254.24 for the last fifty days and a simple moving average of $248.46 for the past two hundred days. Amgen’s 52-week low is $198.64, and its 52-week high is $296.67. The firm’s market capitalization is $153.16 billion, its price-to-earnings ratio is 23.02, its price-to-growth ratio is 2.30, and its beta value is 0.64. There is a debt-to-equity ratio of 10.17, the quick ratio is 1.35, the current ratio is 1.68, and the quick ratio is 1.35.
On Thursday, November 3, Amgen (NASDAQ: AMGN) disseminated its most recent quarterly results report to the public. The medical research company announced quarterly profits per share of $4.70, which is $0.26 better than the forecast of $4.44 that was made by the consensus of analysts. The revenue for the quarter came in at $6.65 billion, which is higher than the $6.56 billion analysts had predicted it would be. The return on equity for Amgen was 287.23%, and the net margin for the company was 24.96%. The quarterly sales for Amgen declined 8% compared to the same period the previous year. During the same period the previous year, the company generated $4.67 per share earnings. Industry experts anticipate that Amgen will generate 17.64 cents per share in the current financial year.
In addition, the business has announced a quarterly dividend, which will be distributed to shareholders on December 8. On Thursday, November 17, shareholders of record will be eligible to receive dividend payments of $1.94 per share. This translates into a dividend payment of $7.76 per year and a yield of 2.70%. The date that constitutes the ex-dividend date for this dividend is November 16. The payout ratio for Amgen at the moment is 62.23%.